ArticleInternational ophthalmology2008
Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.
Article in International ophthalmology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2010Trial
- Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes.Journal of ophthalmology · 2020Article
- ISCEV extended protocol for the stimulus-response series for the dark-adapted full-field ERG b-wave.Documenta ophthalmologica. Advances in ophthalmology · 2019Article
- The effects of bevacizumab treatment in a rat model of retinal ischemia and perfusion injury.Molecular vision · 2018Article
- Intensity response function of the photopic negative response (PhNR): effect of age and test-retest reliability.Documenta ophthalmologica. Advances in ophthalmology · 2017Article
- Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases.Indian journal of ophthalmology · 2017Review
- Progression of impending central retinal vein occlusion to the ischemic variant following intravitreal bevacizumab.Korean journal of ophthalmology : KJO · 2010Article
- Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2010Article
- Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study.International ophthalmology · 2009Article
- [Localisation of bevacizumab in the monkey retina after an intravitreal injection of Avastin].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2009Article
- Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections.Documenta ophthalmologica. Advances in ophthalmology · 2009Article
- Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?Drugs & aging · 2009Review
- Treatment of age-related macular degeneration: focus on ranibizumab.Clinical ophthalmology (Auckland, N.Z.) · 2008Article
- [Intravitreal injection. Monitoring to avoid postoperative complications].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2008Review
- Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBevacizumab (Avastin) has been used as off-label treatment for the specific inhibition of the vascular endothelial growth factor (VEGF). Although only intravenous administration of the drug is approved in combination therapy of colorectal carcinoma, promising short-term results have been reported about its intravitreal administration. However, VEGF is also known to exhibit neurotrophic capabilities. Therefore, blockage of all VEGF isoforms by bevacizumab could induce toxic effects. Missing randomized controlled studies and unclear long-term risks require further evaluation.
methodsIntensified monitoring of bevacizumab treatment was performed in consecutive patients. In ten patients, the functional field score was calculated after obtaining Goldmann visual fields at baseline and 1 year after injection. The other subgroup was examined by means of EOG, ERG and colour testing at baseline and 4 months following treatment. Naka-Rushton plots were calculated to enable statements about retinal function. Lanthony desaturated D15 test was used for repeated colour testing.
resultsBaseline parameters already disclosed predominant cone dysfunction. Drug-related effects caused a significant improvement of visual acuity. There was no sign of clinically relevant retinal toxicity following the bevacizumab injection. No progression of visual field defects was seen within the follow-up of 1 year. Performance in EOG testing was affected by restricted fixation stability, but no parameter indicated deterioration within the 4-month-period.
conclusionsShort-term results underline that intraocular bevacizumab injection promises to be not only a cost-effective, but safe treatment option. Assessed functional parameters as error scores (e.g., Lanthony) corresponded to the impaired retinal function which was presumed to be disease-related. Further long-term results have to confirm the good tolerability in repeated treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.